The effect of nortriptyline and melatonin on diabetic neuropathy

Phase 2

• Conditions: Condition 1: Diabetic polyneuropathy. Condition 2: Diabetic polyneuropathy.; Type 1 diabetes mellitus with diabetic polyneuropathy; Type 2 diabetes mellitus with diabetic polyneuropathy; E10.42; E11.42

• Registration Number: IRCT20191030045277N2
• Lead Sponsor: Babol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

All patients with diabetic neuropathy

Exclusion Criteria

Pregnancy and lactation
Recent Myocardial Infarction
Sensitivity to medications (nortriptyline and melatonin)
History of seizures
Mood disorder
Gastroparesis and diabetic cystopathy,
Liver and Renal failure
hypothyroidism and hyperthyroidism
people with arthritis
Hereditary neuropathies
People with a history of trauma and degenerative bone lesions

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of neuropathy. Timepoint: At the beginning of the study (first day) and at the end of the second week and at the end of the study (end of the fifth week). Method of measurement: Based on the VAS (Visual Analogue Scale).